Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt decreased its stake in Bristol-Myers Squibb (NYSE:BMY) by 4.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,432 shares of the biopharmaceutical company’s stock after selling 800 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Bristol-Myers Squibb were worth $929,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.6% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,681,038 shares of the biopharmaceutical company’s stock worth $264,760,000 after acquiring an additional 27,232 shares during the period. Strategic Financial Concepts LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at $4,377,000. Leo Wealth LLC increased its position in shares of Bristol-Myers Squibb by 51.5% in the fourth quarter. Leo Wealth LLC now owns 14,965 shares of the biopharmaceutical company’s stock valued at $846,000 after buying an additional 5,085 shares in the last quarter. Consolidated Portfolio Review Corp purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $2,379,000. Finally, Measured Wealth Private Client Group LLC grew its stake in Bristol-Myers Squibb by 102.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 11,164 shares of the biopharmaceutical company’s stock valued at $631,000 after acquiring an additional 5,650 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on BMY. Wolfe Research assumed coverage on shares of Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Truist Financial increased their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Bank of America restated a “neutral” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Finally, Morgan Stanley lifted their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $57.86.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $56.96 on Friday. The business’s 50-day simple moving average is $57.61 and its 200-day simple moving average is $53.65. The firm has a market capitalization of $115.51 billion, a P/E ratio of -15.86, a P/E/G ratio of 2.10 and a beta of 0.45. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.10. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. Equities analysts predict that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.35%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -69.08%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.